Northern Trust Corp Buys 143,986 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Northern Trust Corp boosted its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 7.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,004,911 shares of the biotechnology company's stock after buying an additional 143,986 shares during the period. Northern Trust Corp owned approximately 0.97% of BioCryst Pharmaceuticals worth $15,077,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Venturi Wealth Management LLC bought a new position in BioCryst Pharmaceuticals during the fourth quarter valued at approximately $46,000. R Squared Ltd bought a new position in BioCryst Pharmaceuticals during the fourth quarter valued at approximately $48,000. KBC Group NV boosted its stake in BioCryst Pharmaceuticals by 80.1% during the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock valued at $77,000 after buying an additional 4,537 shares during the last quarter. Raymond James Financial Inc. bought a new position in BioCryst Pharmaceuticals during the fourth quarter valued at approximately $80,000. Finally, Syon Capital LLC bought a new position in BioCryst Pharmaceuticals during the fourth quarter valued at approximately $99,000. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Stock Down 2.5%

Shares of NASDAQ:BCRX opened at $10.07 on Thursday. BioCryst Pharmaceuticals, Inc. has a 52-week low of $5.92 and a 52-week high of $11.11. The stock has a market cap of $2.11 billion, a P/E ratio of -16.51 and a beta of 1.08. The business's 50 day moving average is $8.27 and its 200 day moving average is $8.00.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. The company's quarterly revenue was up 40.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.28 earnings per share. On average, sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Needham & Company LLC increased their price target on BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th. Wedbush started coverage on BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They set an "outperform" rating and a $15.00 price objective on the stock. Barclays upped their price objective on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a research report on Wednesday, May 7th. HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $13.00 price objective (up from $11.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $16.56.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.